Page 70 - MEMORIA ANUAL 2020

PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2020
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Outcome of older (≥ 70 years) APL patients frontline treated with or without arsenic trioxide- an International Collaborative Study.
Leukemia. 2020 Sep;34(9):2333-41. doi: 10.1038/s41375-020-0758-4. PMID: 32076120.
Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Adès L, Montesinos P.
• Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic.
Pediatr Blood Cancer. 2020 Sep;67(9):e28557. doi: 10.1002/pbc.28557. PMID: 32672895.
Faura A, Rives S, Lassaletta Á, Sebastián E, Madero L, Huerta J, García-Morín M, Martínez AP, Sisin- ni L, Astigarraga I, Velasco P, Gros L, Moreno L, Carboné A, Rodríguez-Vigil C, Riesco S, Mendoza MDC, Macías EG, Trabazo M, Torrent M, Badell I, Fuster JL, Domínguez-Pinilla N, Juan Ribelles A, Pérez-Alonso V, Fernández Sanmartín M, Baragaño M, Gorostegui M, Pérez-Jaume S, Fernández- Teijeiro A, Morales La Madrid A, Dapena JL.
• Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.
Leukemia. 2020 Sep;34(9):2441-50. doi: 10.1038/s41375-020-0728-x. PMID: 32066866.
Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, Mufti GJ.
• Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality.
Blood Cancer J. 2020 Oct 19;10(10):103. doi: 10.1038/s41408-020-00372-5. PMID: 33077708.
Martínez-López J, Mateos MV, Encinas C, Sureda A, Hernández-Rivas JÁ, López de la Guía A, Con- de D, Krsnik I, Prieto E, Riaza Grau R, Gironella M, Blanchard MJ, Caminos N, Fernández de Larrea C, Senin MA, Escalante F, de la Puerta JE, Giménez E, Martínez-Barranco P, Mateos JJ, Casado LF, Bladé J, Lahuerta JJ, de la Cruz J, San-Miguel J.
• Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Blood Cancer J. 2020 Oct 30;10(10):108. doi: 10.1038/s41408-020-00377-0. PMID: 33127891.
70